Surufatinib + Anti-PD-1/L1
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small Cell Lung Cancer
Conditions
Extensive-Stage Small Cell Lung Cancer
Trial Timeline
Sep 27, 2022 → Jul 31, 2024
NCT ID
NCT05509699About Surufatinib + Anti-PD-1/L1
Surufatinib + Anti-PD-1/L1 is a phase 2 stage product being developed by HUTCHMED for Extensive-Stage Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05509699. Target conditions include Extensive-Stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 7 similar drugs in Extensive-Stage Small Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05509699 | Phase 2 | Completed |
Competing Products
20 competing products in Extensive-Stage Small Cell Lung Cancer